img_hblbg.jpg
logo.jpg
img_hbrbg.jpg
Home > Pharmacovigilance
img_blueB.jpg

Pharmacovigilance

pharmacovigilance.jpg

img_blueB.jpg
img_inp_rblbg.jpg

Latest @ Ipca

Ipca - Ratlam formulations plant ranked third position in the National Energy Conservation Award - 2010.

img_inp_rblbg.jpg

Pharmacovigilance

At Ipca Laboratories Ltd., our commitment to ensuring safety of drugs goes beyond mere compliance. We understand the need and importance of monitoring drug safety - right from the discovery of the medicine throughout the life of the drug.

Drug safety is an important consideration for all stakeholders involved with drugs, right from the health care professionals, who are medically qualified persons, such as physicians, dentists, pharmacists, nurses and coroners to patients who consume the drug, to drug regulatory authorities and pharmaceutical companies who are involved in manufacturing and marketing of the drugs.

Though drugs come to clinical practice only after they are proven safe in clinical trials, rare adverse events can surface anytime during their life cycle. All drugs are normally associated with the possibility of adverse events and are prescribed only when the beneficial effects override consideration of any adverse events, which may result from its use.

Pharmacovigilance activity has hence been initiated by Ipca as a dedicated function to ensure consistent drug safety.

Pharmacovigilance function comprises of the following:

  • Detection
  • Assessment & evaluation
  • Understanding and
  • Prevention

We have comprehensive systems in place for detecting and rapidly evaluating potential risk due to adverse report of medicines.

We assess the adverse event reports received from health care professionals and consumers from countries, where Ipca's products are marketed. We review the adverse event reports published in medical journals and scientific literature. We also evaluate safety of our products through clinical trials and post marketing surveillance studies. We train our sales representatives, both in domestic and international market on various aspects of pharmacovigilance and how to do adverse event reporting. Necessary actions are taken based on the assessment of the adverse event reports.

With above activities, we try to ensure safe and rational use of medicines.

If you wish to report a suspected adverse reaction occurred with our drug, please download the Adverse Event Reporting Form, complete it, and send it to us in any one of the following ways:

(Click to download Adverse Event Reporting Form)

All the information and personal data you share with us in your enquiry information will be protected and kept confidential in line with Company SOP. The information you provide will be used for the purpose of drug safety surveillance [and to enable us to deal with your enquiry appropriately] and it may be shared with health authorities. You have a right of access to your personal data which we hold about you.

*In case, you are not able to download the Adverse Event Reporting Form, you can even obtain it by choosing any mode (Representative, Phone, Fax, Email) as mentioned below.

  • Call: +91 22 6647 4630
  • Fax the form on Fax No. +91 22 2868 6954 / 2868 2875
  • Scan the form and email at pharmacovigilance.mumbai@ipca.com
  • Courier the form at:
    Corporate Pharmacovigilance Cell
    Ipca Laboratories Limited
    142-AB, Kandivli Industrial Estate
    Kandivli (West)
    Mumbai 400 067
    India

or Fill it here

Note: Fields marked by * are compulsory

Patient's Initial *
 
Adverse event *
 
Suspect drugs *
 
Name of the reporter *
 
Email ID of the reporter *
 
Telephone/Cell number of the reporter *
 
 
Copyright © Ipca Laboratories Ltd. 2012. All Rights Reserved.